Home › Research › Treatments
Galantamine treatment of vascular dementia: a randomized trial
Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C, GAL-INT-26 Study Group.. Neurology, 2007-07-01
Topic: Risk, prevention and care in population studies
Background To evaluate efficacy and safety of galantamine for patients with vascular dementia (VaD). Methods In this multinational, randomized, double-blind, placebo-controlled, parallel-group clinical trial, 788 patients with probable VaD who also satisfied strict centrally read MRI criteria were randomized to receive galantamine or placebo. Efficacy was evaluated using measures of cognition, daily function, and behavior.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Auchus, A. P., Brashear, H. R., Salloway, S., Korczyn, A. D., De Deyn, P. P., Gassmann-Mayer, C., et al. (2007). Galantamine treatment of vascular dementia: a randomized trial. Neurology. https://doi.org/10.1212/01.wnl.0000266625.31615.f6
Vancouver
Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C, et al. Galantamine treatment of vascular dementia: a randomized trial. Neurology. 2007. doi:10.1212/01.wnl.0000266625.31615.f6. PMID: 17664404.
BibTeX
@article{auchus2007-17664404,
author = {Auchus, A. P. and Brashear, H. R. and Salloway, S. and Korczyn, A. D. and De Deyn, P. P. and Gassmann-Mayer, C. and {GAL-INT-26 Study Group}},
title = {{Galantamine treatment of vascular dementia: a randomized trial}},
journal = {Neurology},
year = {2007},
doi = {10.1212/01.wnl.0000266625.31615.f6},
pmid = {17664404},
url = {https://doi.org/10.1212/01.wnl.0000266625.31615.f6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Methods In this multinational, randomized, double-blind, placebo-controlled, parallel-group clinical trial, 788 patients with probable VaD who also satisfied strict centrally read MRI criteria were randomized to receive galantamine or placebo.
- Efficacy was evaluated using measures of cognition, daily function, and behavior.
- The primary efficacy measures were the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog/11) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) total score.
- Secondary outcomes included the Clinician's Interview Based on Impression of Change-Plus Caregiver Input (CIBIC-plus), Neuropsychiatric Inventory, and EXIT-25 for assessment of executive functioning.
Why it matters
This randomized trial gave galantamine or placebo to 788 patients with vascular dementia, a different condition from Alzheimer's disease. It tested effects on cognition, daily function, and behavior, but the provided findings do not report whether galantamine worked, so no conclusion about treating Alzheimer's disease can be drawn.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants788
- Evidence strengthHigh
How this study scored 69/100
Published in a leading specialty journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2007 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 788 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 5 / 7 | Cited 189 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 9.0 citations a year over 21 year(s) since 2007 |
| Impact for its field and year | 3 / 6 | Cited 6.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 20 other studies in this library |
| Still being cited | 2 / 4 | Cited 24 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Cristiana Gassmann-Mayer: h-index 16 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Tel Aviv University: institution h-index 1,018 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 17664404) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 69 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
20 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments
Also tagged “placebo-controlled”
783 studies in the library carry the topic tag “placebo-controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.